Sarepta's Duchenne Franchise Now Carries the Weight of Every Gene Therapy Disappointment
Sarepta Therapeutics (SRPT) reports second-quarter 2026 earnings after the close on August 5, with analysts expecting $0.34 per share — a dramatic 80% decline from the $1.70 reported in the same quarter last year. The central question: can the biotech company stabilize profitability after a volatile year marked by extreme earnings swings, or will investors face another quarter of disappointing results that have sent the stock tumbling 15% below its 200-day moving average?
Part 1: Earnings Preview
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on precision genetic medicine for rare diseases, particularly Duchenne muscular dystrophy (DMD). The company markets multiple approved therapies and maintains a robust pipeline of gene therapy candidates that drive both revenue growth and significant R&D expenses.
Sarepta reports Q2 2026 results after market close on August 5, with the consensus calling for $0.34 per share on revenue estimates averaging $365.45 million (down 40.2% year-over-year). The company most recently reported $3.09 per share for Q1 2026, crushing estimates by 692%. However, that massive beat followed a disastrous Q4 2025 loss of $3.87 per share. The year-over-year comparison is stark: analysts expect earnings to plunge 80% from the $1.70 reported in Q2 2025, reflecting the company's ongoing struggle to achieve consistent profitability despite growing its commercial franchise.
Three key themes define this earnings story:
Gene Therapy Commercial Execution: Investors are watching whether Sarepta can sustain momentum from its gene therapy portfolio, particularly Elevidys, which has driven recent revenue growth but faces reimbursement challenges and manufacturing scale-up questions that directly impact profitability.
R&D Spending and Pipeline Progress: The company's aggressive investment in clinical programs has created extreme earnings volatility. Analysts are focused on whether management can balance pipeline advancement with improved cost discipline, especially after the Q4 2025 loss shocked the Street.
Path to Sustainable Profitability: With full-year 2026 estimates calling for $3.89 per share versus a $6.29 loss in 2025, the market is questioning whether Sarepta can deliver consistent positive earnings or if the recent quarters represent one-time benefits rather than a sustainable trend.
Analyst commentary ahead of the release reflects cautious optimism tempered by execution concerns. While the company's gene therapy franchise represents a significant commercial opportunity, the wide dispersion in estimates — ranging from $0.24 to $0.53 per share — signals uncertainty about near-term profitability. Several analysts have noted that revenue growth alone won't satisfy investors without corresponding margin improvement and clearer visibility into the path toward sustained profitability.
Part 2: Historical Earnings Performance
Sarepta's recent earnings history reveals extreme volatility that has whipsawed investors across four consecutive quarters. The company has alternated between massive beats and devastating misses, with surprise percentages ranging from +692% to -276% — a pattern that suggests either highly conservative guidance or significant quarter-to-quarter variability in the business model.
The most recent quarter (Q1 2026) delivered a stunning $3.09 per share against a $0.39 estimate, marking a 692% beat. However, this followed a catastrophic Q4 2025 result of -$3.87 per share versus a -$1.03 estimate, a 276% miss that likely triggered the stock's technical breakdown. The prior two quarters showed more modest beats: Q3 2025 came in at -$0.28 versus -$0.37 (24% beat), while Q2 2025 posted $1.70 against a $0.78 estimate (118% beat).
The pattern suggests no reliable trend — Sarepta has beaten estimates in three of the last four quarters, but the magnitude of both beats and misses indicates the company's earnings remain highly unpredictable. The upcoming quarter's 80% year-over-year decline in the consensus estimate reflects analysts' attempt to account for this volatility, but the wide range between the $0.24 low and $0.53 high estimate shows the Street remains deeply uncertain about what Sarepta will actually deliver.
| Quarter | EPS Estimate | EPS Actual | Surprise % | Beat/Miss |
|---|---|---|---|---|
| Jun 2025 | $0.78 | $1.70 | +117.95% | Beat |
| Sep 2025 | $-0.37 | $-0.28 | +24.32% | Beat |
| Dec 2025 | $-1.03 | $-3.87 | -275.73% | Miss |
| Mar 2026 | $0.39 | $3.09 | +692.31% | Beat |
Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
Sarepta reports after market close, meaning Day 0 captures anticipatory trading before results drop, while Day +1 represents the first full session where the market digests actual results.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-05-06 | +$1.24 (+5.69%) | $1.85 (8.49%) | -$2.23 (-9.68%) | $2.55 (11.07%) |
| 2026-02-25 | +$0.13 (+0.69%) | $0.52 (2.76%) | -$1.52 (-8.01%) | $1.48 (7.80%) |
| 2025-11-03 | +$0.44 (+1.83%) | $1.88 (7.83%) | -$8.25 (-33.74%) | $2.67 (10.92%) |
| 2025-08-06 | -$0.49 (-2.93%) | $0.93 (5.58%) | +$1.70 (+10.46%) | $2.09 (12.85%) |
| 2025-05-06 | -$16.91 (-26.56%) | $17.40 (27.33%) | -$10.03 (-21.45%) | $3.41 (7.30%) |
| 2025-02-26 | -$0.09 (-0.08%) | $3.18 (2.97%) | -$3.80 (-3.56%) | $8.50 (7.95%) |
| 2024-11-06 | +$2.96 (+2.37%) | $5.87 (4.70%) | -$7.55 (-5.90%) | $15.48 (12.10%) |
| 2024-08-07 | -$2.79 (-1.95%) | $5.09 (3.56%) | -$3.66 (-2.61%) | $7.59 (5.42%) |
| Avg Abs Move | 5.26% | 7.90% | 11.93% | 9.43% |
Historical price action around Sarepta earnings shows significant volatility, with an average absolute Day 0 move of 5.26% and Day +1 move of 11.93%. The most dramatic reaction came after the May 2025 report, when the stock plunged 26.56% on Day 0 and continued falling 21.45% on Day +1 — a two-day collapse that erased nearly half the stock's value. More recently, the May 2026 report triggered a 5.69% Day 0 gain followed by a 9.68% Day +1 decline, illustrating how initial optimism can quickly reverse.
The pattern reveals asymmetric risk: while positive surprises have generated modest single-digit gains, negative surprises have triggered double-digit declines. The November 2025 earnings particularly stand out, with a modest 1.83% Day 0 gain followed by a devastating 33.74% Day +1 collapse. Investors should prepare for substantial volatility, with the historical data suggesting downside moves tend to be larger and more sustained than upside reactions.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 08/07/26 (DTE 3) |
| Expected Move | $0.77 (4.67%) |
| Expected Range | $15.63 to $17.16 |
| Implied Volatility | 150.28% |
The options market is pricing a 4.67% expected move for this earnings release, which sits below the 5.26% average Day 0 move and well below the 11.93% average Day +1 move from recent history. This suggests options traders may be underpricing the potential volatility, particularly given Sarepta's track record of extreme post-earnings swings that have exceeded 20% in multiple recent quarters.
Part 3: What Analysts Are Saying
Analysts maintain a cautious stance on Sarepta heading into earnings, with the average recommendation at 3.35 (between Hold and Buy) based on 26 ratings. The consensus price target of $21.83 implies 33% upside from the current $16.39 price, though the wide range between the $5.00 low and $38.00 high target reflects deep disagreement about the company's prospects.
The rating breakdown shows a divided Street: 9 analysts rate the stock a Strong Buy, while 12 maintain Hold ratings, 1 rates it a Moderate Sell, and 4 assign Strong Sell ratings. This polarization — with roughly equal numbers of bulls and bears — underscores the uncertainty surrounding Sarepta's ability to deliver consistent profitability.
Sentiment has improved over the past month, with Strong Buy ratings increasing from 7 to 9 while Hold ratings declined from 15 to 12. However, the average recommendation actually weakened slightly from 3.19 to 3.35, suggesting the improvement is modest and the analyst community remains fundamentally uncertain about the stock's direction. The persistence of 4 Strong Sell ratings even after the sentiment improvement indicates a meaningful cohort of analysts expects continued disappointment.
Part 4: Technical Picture
The Barchart Technical Opinion shows an 88% Sell signal, unchanged from last week but significantly deteriorated from the 40% Sell reading a month ago. This sharp weakening reflects the stock's inability to hold key support levels as it trades at $16.39, well below most major moving averages.
Timeframe Analysis:
- Short-term (50% Sell): Moderate sell signal indicates near-term momentum has turned negative, though not at extreme levels
- Medium-term (100% Sell): Strong sell signal across all medium-term indicators suggests the intermediate trend has decisively broken down
- Long-term (100% Sell): Maximum bearish reading reflects severe technical damage to the longer-term uptrend
Trend Characteristics: The trend shows Average strength but is Weakening, indicating the selling pressure is building rather than stabilizing — a concerning setup heading into a high-stakes earnings event.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $15.64 | 50-Day MA | $16.90 |
| 10-Day MA | $15.69 | 100-Day MA | $18.48 |
| 20-Day MA | $16.92 | 200-Day MA | $19.36 |
SRPT trades below its 20-day ($16.92), 50-day ($16.90), 100-day ($18.48), and 200-day ($19.36) moving averages, though it has recently bounced above the 5-day ($15.64) and 10-day ($15.69) averages. The stock sits 15% below its 200-day moving average, a level that typically signals significant technical damage. The convergence of the 20-day and 50-day moving averages near $16.90 creates immediate overhead resistance, while the 200-day average at $19.36 represents a major hurdle for any sustained recovery. With all medium- and long-term indicators flashing maximum bearish readings and the stock trapped below a dense cluster of resistance, the technical setup is decidedly cautionary heading into earnings — any disappointment could trigger another leg down toward the recent lows, while even a strong beat may struggle to generate sustained upside given the damaged chart structure.
